Radiation induced lung reactions in breast cancer therapy. Modulating factors and consequential effects
- PMID: 16170483
- DOI: 10.1007/s00066-005-1457-9
Radiation induced lung reactions in breast cancer therapy. Modulating factors and consequential effects
Abstract
Background and purpose: Radiologic reactions in lung, usually subclinical, are a frequent side effect of radiotherapy for breast cancer. This study was initiated to identify effects of age and tamoxifen on radiation pneumonitis and consequent fibrosis.
Patients and methods: Retrospectively, 451 patients irradiated postoperatively between 1992 and 1995 at the Department of Radiotherapy of Carl-Thiem-Klinikum (Cottbus, Germany) were analyzed. The median age was 58 years. After mastectomy (n = 296), 25 x 2.0 Gy were applied; breast-conserving surgery (n = 155) was followed by 30 x 2.0 Gy. In 221 patients, adjuvant tamoxifen was given. Follow-up included thorax radiography after 15 weeks and 1 year. In patients with reversible observations in standard chest radiography from 15 weeks to 1 year, CT or high-resolution (HR-)CT scans were analyzed after 4-7 years.
Results: Clinical symptoms of pneumonitis were seen in 25 patients (5.5%), all with radiologic changes. Early radiologic changes were detected in 134 patients (29.7%). Age (> 58 years; p = 0.0127) and tamoxifen (p = 0.0001) were found as significant parameters of early pneumopathy. Late radiologic changes were seen in 94/425 patients (22.1%), all after a positive early reaction (p = 0.001).
Conclusion: A low incidence of clinically symptomatic pneumonitis was observed, while the vast majority of patients presented with early radiologic changes. Higher age and tamoxifen treatment significantly increased the incidence of early pneumopathy. Local fibrotic responses must be expected in all patients with early reactions, indicating a strong consequential component of the late reaction.
Similar articles
-
Breast cancer: high resolution CT in association with spirometric tests in the assessment of post-radiation pulmonary fibrosis.Radiol Med. 2005 Sep;110(3):156-69. Radiol Med. 2005. PMID: 16200038 English, Italian. No abstract available.
-
Radiotherapy-related lung fibrosis enhanced by tamoxifen.J Natl Cancer Inst. 1996 Jul 3;88(13):918-22. doi: 10.1093/jnci/88.13.918. J Natl Cancer Inst. 1996. PMID: 8656444 Clinical Trial.
-
Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.Acta Oncol. 2007;46(4):525-33. doi: 10.1080/02841860701291698. Acta Oncol. 2007. PMID: 17497320
-
[On the interaction of adjuvant radiotherapy and tamoxifen treatment for breast cancer].Strahlenther Onkol. 2007 Oct;183(10):535-44. doi: 10.1007/s00066-007-1710-5. Strahlenther Onkol. 2007. PMID: 17896084 Review. German.
-
Radiotherapy and tamoxifen after breast-conserving surgery for DCIS.Int J Fertil Womens Med. 2004 Sep-Oct;49(5):237-8. Int J Fertil Womens Med. 2004. PMID: 15633483 Review.
Cited by
-
Meta-analysis of incidence of early lung toxicity in 3-dimensional conformal irradiation of breast carcinomas.Radiat Oncol. 2013 Nov 14;8:268. doi: 10.1186/1748-717X-8-268. Radiat Oncol. 2013. PMID: 24229418 Free PMC article.
-
Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy.Radiother Oncol. 2009 Jun;91(3):427-32. doi: 10.1016/j.radonc.2008.09.009. Epub 2008 Oct 18. Radiother Oncol. 2009. PMID: 18937989 Free PMC article.
-
Is prone free breathing better than supine deep inspiration breath-hold for left whole-breast radiotherapy? A dosimetric analysis.Strahlenther Onkol. 2021 Apr;197(4):317-331. doi: 10.1007/s00066-020-01731-8. Epub 2021 Jan 8. Strahlenther Onkol. 2021. PMID: 33416915 Free PMC article. Clinical Trial.
-
Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma.Radiat Oncol. 2007 Jan 3;2:2. doi: 10.1186/1748-717X-2-2. Radiat Oncol. 2007. PMID: 17201913 Free PMC article.
-
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.J Clin Oncol. 2009 Jun 1;27(16):2638-44. doi: 10.1200/JCO.2008.17.9549. Epub 2009 Apr 6. J Clin Oncol. 2009. PMID: 19349549 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical